Assessment of Enterovirus Excretion and Identification of VDPVs in Patients with Primary Immunodeficiency in India: Outcome of ICMR-WHO Collaborative Study Phase-I.
AFP surveillance
Global Polio Eradication Initiative (GPEI)
Oral Polio Vaccine (OPV)
combined immunodeficiency (CID)
enteroviruses
iVDPV surveillance
immunodeficiency-related vaccine-derived polioviruses (iVDPV)
inborn errors of immunity (IEI)
polio eradication
primary immunodeficiency disorder (PID)
prolonged excretion
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
06 Jul 2023
06 Jul 2023
Historique:
received:
07
03
2023
revised:
27
04
2023
accepted:
28
04
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
The emergence of vaccine-derived polioviruses (VDPVs) in patients with Primary Immunodeficiency (PID) is a threat to the polio-eradication program. In a first of its kind pilot study for successful screening and identification of VDPV excretion among patients with PID in India, enteroviruses were assessed in stool specimens of 154 PID patients across India in a period of two years. A total of 21.42% of patients were tested positive for enteroviruses, 2.59% tested positive for polioviruses (PV), whereas 18.83% of patients were positive for non-polio enteroviruses (NPEV). A male child of 3 years and 6 months of age diagnosed with Hyper IgM syndrome was detected positive for type1 VDPV (iVDPV1) with 1.6% nucleotide divergence from the parent Sabin strain. E21 (19.4%), E14 (9%), E11 (9%), E16 (7.5%), and CVA2 (7.5%) were the five most frequently observed NPEV types in PID patients. Patients with combined immunodeficiency were at a higher risk for enterovirus infection as compared to antibody deficiency. The high susceptibility of PID patients to enterovirus infection emphasizes the need for enhanced surveillance of these patients until the use of OPV is stopped. The expansion of PID surveillance and integration with a national program will facilitate early detection and follow-up of iVDPV excretion to mitigate the risk for iVDPV spread.
Identifiants
pubmed: 37515027
pii: vaccines11071211
doi: 10.3390/vaccines11071211
pmc: PMC10383878
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Références
Lancet Infect Dis. 2022 Jan;22(1):e35-e40
pubmed: 34265258
J Clin Immunol. 2018 Jul;38(5):628-634
pubmed: 30006913
PLoS Pathog. 2018 Mar 19;14(3):e1006943
pubmed: 29554133
MMWR Morb Mortal Wkly Rep. 2022 Sep 09;71(36):1148-1150
pubmed: 36074738
Open Forum Infect Dis. 2018 Oct 01;5(10):ofy250
pubmed: 30377626
Front Immunol. 2017 Jun 13;8:685
pubmed: 28952612
Emerg Infect Dis. 2017 Oct;23(10):1664-1670
pubmed: 28930011
N Engl J Med. 1994 Apr 21;330(16):1107-13
pubmed: 8133853
Ann Allergy Asthma Immunol. 2011 Jun;106(6):544-5
pubmed: 21624761
Sci Rep. 2017 Jun 19;7(1):3808
pubmed: 28630462
Appl Environ Microbiol. 2017 Feb 15;83(5):
pubmed: 28039136
Expert Rev Clin Immunol. 2019 May;15(5):529-540
pubmed: 30681380
BMC Infect Dis. 2022 Nov 8;22(1):821
pubmed: 36348312
Front Immunol. 2017 Sep 25;8:1103
pubmed: 28993765
Nat Rev Microbiol. 2018 Jun;16(6):368-381
pubmed: 29626210
MMWR Morb Mortal Wkly Rep. 2020 Jul 17;69(28):913-917
pubmed: 32673297
Immunol Rev. 2005 Feb;203:48-66
pubmed: 15661021
MMWR Morb Mortal Wkly Rep. 2020 May 22;69(20):623-629
pubmed: 32437342
Wkly Epidemiol Rec. 2015 May 29;90(22):261-78
pubmed: 26027016
J Infect Dis. 2014 Nov 1;210 Suppl 1:S373-9
pubmed: 25316858
Methods Mol Biol. 2016;1387:145-76
pubmed: 26983734
Viruses. 2021 Feb 27;13(3):
pubmed: 33673590
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1129-1135
pubmed: 34437527
Appl Environ Microbiol. 2017 Jun 16;83(13):
pubmed: 28432101
Euro Surveill. 2016 Nov 17;21(46):
pubmed: 27918255
MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1330-1333
pubmed: 32941411
Front Immunol. 2019 Jul 23;10:1567
pubmed: 31396204
J Clin Immunol. 2022 Oct;42(7):1473-1507
pubmed: 35748970
Vaccine. 2015 Mar 3;33(10):1235-42
pubmed: 25600519
BMC Res Notes. 2018 Oct 11;11(1):717
pubmed: 30305145